K-Ras and β-catenin mutations cooperate with Fgfr3 mutations in mice to promote tumorigenesis in the skin and lung, but not in the bladder

K-Ras and β-catenin mutations cooperate with Fgfr3 mutations in mice to promote tumorigenesis in the skin and lung, but not in the bladder. Disease

غربالگری غیر تهاجمی مارکر تومور S249C ژن FGFR3 به روش TETRA-ARMS-PCR در سلول‌های اپی‌تلیال ادراری در بدخیمی مثانه

Abstract Introduction: Genetic variation of FGFR3 gene is one of the factors affecting the bladder tumor. FGFR3 is a tyrosine kinase receptor, involved in controlling the cellular and angiogenesis cycle. This protein affects a variety of diseases and cancers and cartilage growth abnormalities. Regarding the high activity of fgfr3 mutations in more than 50% of primary tumors of bladder urethral...

Prevalence of K-RAS mutations and CA125 tumor marker in patients with ovarian carcinoma

Background: Ovarian carcinoma is one of the leading causes of cancer-related death among females. K-ras codon 12 mutations are commonly occurring mutations in different types of cancers and leads to resistance against anti-EGFR therapeutics. Hence, determination of mutations in k-ras gene is crucial for predicting response to anti-EGFR therapies. This study aimed to evaluate the prevalence of k...

KY1022, a small molecule destabilizing Ras via targeting the Wnt/β-catenin pathway, inhibits development of metastatic colorectal cancer

APC (80-90%) and K-Ras (40-50%) mutations frequently occur in human colorectal cancer (CRC) and these mutations cooperatively accelerate tumorigenesis including metastasis. In addition, both β-catenin and Ras levels are highly increased in CRC, especially in metastatic CRC (mCRC). Therefore, targeting both the Wnt/β-catenin and Ras pathways could be an ideal therapeutic approach for treating mC...

K-ras Mutation in Colorectal Cancer, A Report from Southern Iran

There are very few studies about K-ras mutations in colorectal cancer (CRC) from developing countries such as Iran. It is therefore essential to conduct studies to learn about the molecular signature of such tumors, allowing the determination of an appropriate management plan. In the present study, we aimed to determine the frequency and types of K-ras mutations among patients with CRC in Iran....